The unknown consequences of COVID-19 in people with Autism Spectrum Disorders
Alterations in the immune system are often found in children with Autism Spectrum Disorders [ASD], leading to an aberrant immune response which compromises host defense. Fewer regulatory T-cells, elevation in inflammatory cells and proinflammatory cytokines have been highly reported in this populati...
Gespeichert in:
Veröffentlicht in: | Revista Investigación y Desarrollo 2022-10, Vol.12 (1), p.85-87 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | spa |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Alterations in the immune system are often found in children with Autism Spectrum Disorders [ASD], leading to an aberrant immune response which compromises host defense. Fewer regulatory T-cells, elevation in inflammatory cells and proinflammatory cytokines have been highly reported in this population and it has been recently seen as a chronic neuroinflammatory disorder. Cytokines are often dysregulated in ASD especially IL-6, which is one of the biggest concerns during the current COVID-19 pandemic, as well as other immune dysregulations. We strongly believe that this proinflammatory environment in ASD could increase the vulnerability of a poor clinical outcome for COVID-19 infection.
Las alteraciones en el sistema inmunitario se encuentran a menudo en niños con trastornos del espectro autista [TEA], lo que conduce a una respuesta inmune aberrante que compromete la defensa del huésped. Menos células T reguladoras, elevación en las células inflamatorias y citoquinas proinflamatorias han sido muy reportados en esta población y se ha visto recientemente como un trastorno neuroinflamatorio crónico. Las citocinas a menudo están desreguladas en el TEA, especialmente la IL-6, que es una de las mayores preocupaciones durante la pandemia actual del COVID-19, así como otras desregulaciones inmunes. Creemos firmemente que este entorno proinflamatorio en TEA podría aumentar la vulnerabilidad de un resultado clínico pobre para la infección por COVID-19. |
---|---|
ISSN: | 1390-5546 2631-2557 |
DOI: | 10.31243/id.v12.2020.989 |